Brain metastasis (BM) is a common complication in non-small cell lung cancer (NSCLC), which associates with poor prognosis. Recently, immune checkpoint inhibitors (ICIs) has revolutionized the treatment of tumors. Programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors could produce antitumor effect by activating the autoimmune system. The immunotherapy has already show to have a promising outcome for NSCLC patients with BM, while its specific curative effect and the most ideal mode of the treatment remain to be explored. Here we reviewed the tumor microenvironment (TME) in BM lesions and summarized the role of PD-1/PD-L1 inhibitors in cerebral and its current status in clinical studies. .
【中文题目：PD-1/PD-L1抑制剂治疗NSCLC脑转移的 免疫机制与临床研究进展】 【中文摘要：脑转移是非小细胞肺癌（non-small cell lung cancer, NSCLC）的常见并发症，预后较差。近年来，免疫检查点抑制剂将恶性肿瘤的治疗带入新纪元。程序性死亡因子-1（programmed death-1, PD-1）/程序性死亡因子配体-1（programmed death ligand 1, PD-L1）抑制剂通过激活自身免疫系统，产生抗肿瘤效应。PD-1/PD-L1抑制剂在NSCLC脑转移治疗中初露锋芒，但其确切疗效及最佳治疗模式仍有待进一步研究。本文针对NSCLC脑转移灶的免疫微环境，PD-1/PD-L1抑制剂在颅内的作用机制及其临床研究现状进行综述。 】 【中文关键词：肺肿瘤；脑转移；免疫治疗；PD-1/PD-L1】.
Keywords: Brain metastasis; Immunotherapy; Lung neoplasms; PD-1/PD-L1.